Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with ...

EVERSANA, a purpose-built, partner-led commercial organization, positions Candel for potential U.S. commercial launch following planned BLA ...

Full abstracts will be released by ASCO on Thursday, May 22, 2025, at 5:00 PM ET. Details from the presentations will be available following the event on the Candel website at Candel Media. * Dr.

Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for ...

Century Therapeutics, Candel Therapeutics and MacroGenics have all used their third-quarter earnings releases to disclose how they’re fine-tuning their clinical pipelines to conserve cash. Century has ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Candel Therapeutics, Inc. (NASDAQ:CADL) shares are trading higher Thursday after the company received FDA orphan drug designation for CAN-2409 for the treatment of pancreatic cancer. "We recently ...

Candel Therapeutics is taking difficult measures to keep its clinical flame burning, laying off 50% of its team as part of a wide scale restructuring meant to save cash for a couple of core programs.

A clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion. Focused on the development of multimodal biological immunotherapies to help ...

Investors might want to bet on Candel Therapeutics, Inc. (CADL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in ...

RTW committed $100M in U.S. launch funding, subject to U.S. Food and Drug Administration (FDA) approval of aglatimagene besadenovec (aglatimagene or CAN-2409) for intermediate- to high-risk localized ...

NEEDHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ("Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...